0.000
0.00 (0.00%)
| Price / Sales | 11.21 |
| Price / Book | 9.62 |
| Profit Margin | -297.77% |
| Operating Margin (TTM) | -493.76% |
| Diluted EPS (TTM) | 0.000 |
| Quarterly Revenue Growth (YOY) | -57.20% |
| Total Debt/Equity (MRQ) | 131.78% |
| Current Ratio (MRQ) | 3.62 |
| Operating Cash Flow (TTM) | -3.67 M |
| Levered Free Cash Flow (TTM) | -4.48 M |
| Return on Assets (TTM) | -38.72% |
| Return on Equity (TTM) | -322.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (AU) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | LABTECH FPO [LBT] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.75 |
Select this tab to load the latest available analysis.
|
LBT Innovations Ltd is a designer of technology solutions for the medical industry. Its first product, MicroStreak, in the automation of the culture plate streaking process. Its second product, the Automated Plate Assessment System(APAS) is based upon LBT's intelligent imaging and machine learning software and remains the only U.S. FDA-cleared artificial intelligence technology for automated imaging, analysis, and interpretation of microbiology culture plates following incubation. The company operates in Australia, U.S., Sweden, UK, and Germany. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 60.66% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |